Laromestrocel is under clinical development by Longeveron and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Laromestrocel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Laromestrocel overview

Lomecel-B is under development for the treatment of hypoplastic left heart syndrome in infants, unspecified influenza virus infections and Alzheimer's disease. It is administered through intramyocardial and intravenous route. The drug candidate comprises of allogeneic human mesenchymal stem cells (hMSC).

It was under development for the treatment of ageing frailty, acute respiratory distress syndrome caused by coronavirus disease 2019 (COVID-19).

Longeveron overview

Longeveron is a biotechnology company. It discovers and develops cellular therapies for aging-related and life-threatening conditions. The company’s lead investigational product is LOMECEL-B, a cell-based therapy against aging-related chronic diseases. It is also conducting clinical research in the following indications/conditions: aging frailty, alzheimer’s disease, metabolic syndrome, acute respiratory distress syndrome (ARDS) and hypoplastic left heart syndrome (HLHS). Longeveron works in collaboration with pharmaceutical and biotechnology companies to develop its products. The company operates through manufacturing plants in Miami, Florida, the US. Longeveron is headquartered in Miami, Florida, the US.

For a complete picture of Laromestrocel’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.